drugset
Drugs / Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
last change Jun 2021 re-read 3 minutes ago

Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

also known as FRSW107

Protein / enzyme biologic

Developed for
hemophilia A
Investigated by
Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Zhengzhou Gensciences Inc

Trials 1

today NCT04845399 · Ph 3
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04845399 Apr → Jun 2021 hemophilia A Zhengzhou Gensciences Inc Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant Human Coagulation Factor VIII-Fc Fusion Protein ClinicalTrials.gov intervention name — accepted as the source's own label NCT04845399 ↗
Known as FRSW107 “Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107)” NCT04845399 ↗
Modality Protein / enzyme biologic “Recombinant Human Coagulation Factor VIII-Fc Fusion Protein” NCT04845399 ↗